J-L. Pujol

849 total citations · 1 hit paper
15 papers, 658 citations indexed

About

J-L. Pujol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, J-L. Pujol has authored 15 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in J-L. Pujol's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Brain Metastases and Treatment (2 papers). J-L. Pujol is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (5 papers) and Brain Metastases and Treatment (2 papers). J-L. Pujol collaborates with scholars based in France, Spain and United States. J-L. Pujol's co-authors include Élisabeth Quoix, Jean‐Christophe Grenier, Fabrice Barlési, G Buccheri, Olivier Molinier, Daurès Jp, T. Muley, M Paesmans, M Szturmowicz and W. Ébert and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

J-L. Pujol

14 papers receiving 645 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers

Countries citing papers authored by J-L. Pujol

Since Specialization

Citations

This map shows the geographic impact of J-L. Pujol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J-L. Pujol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J-L. Pujol more than expected).

Fields of papers citing papers by J-L. Pujol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J-L. Pujol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J-L. Pujol. The network helps show where J-L. Pujol may publish in the future.

Co-authorship network of co-authors of J-L. Pujol

This figure shows the co-authorship network connecting the top 25 collaborators of J-L. Pujol. A scholar is included among the top collaborators of J-L. Pujol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J-L. Pujol. J-L. Pujol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study 2024 ·Annals of Oncology ·Mariano Provencio, Mark M. Awad, Tina Cascone, (unknown), Jie He, Shun Lü, Aurelia Alexandru, (unknown), Robin Cornelissen, Lía Raquel Oliveira, (unknown), J-L. Pujol, (unknown), Jhanelle E. Gray, C. Coronado Erdmann, (unknown), (unknown), (unknown), Fumihiro Tanaka	9
2	LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study 2024 ·ESMO Open ·Mark M. Awad, Tina Cascone, Jonathan Spicer, Jie He, Shun Lü, Fumihiro Tanaka, Robin Cornelissen, (unknown), (unknown), Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, T-E. Ciuleanu, (unknown), Annelies Janssens, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, Mariano Provencio	2
3	OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial 2024 ·Journal of Thoracic Oncology ·(unknown), Giuseppe Lo Russo, H. Léna, (unknown), (unknown), Dariusz M. Kowalski, Michael E. Johnson, Silvia Novello, (unknown), (unknown), J-L. Pujol, (unknown), (unknown), (unknown), Byoung Chul Cho	4
4	121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC 2024 ·ESMO Open ·(unknown), Mariano Provencio, Mark M. Awad, Jie He, Shun Lu, (unknown), Robin Cornelissen, Luboš Petruželka, (unknown), Lin Wu, J-L. Pujol, Hiroyuki Ito, T-E. Ciuleanu, (unknown), Annelies Janssens, Steven I. Blum, L. Vo, C. Coronado Erdmann, S. Meadows–Shropshire, Tina Cascone	0
5	LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC breakdown → 2023 ·Annals of Oncology ·Tina Cascone, Mark M. Awad, (unknown), Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, (unknown), Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, (unknown)	67
6	Tomosynthèse : luxe ou nécessité 2009 ·Journal de Radiologie ·Patrice Taourel, S. Mérigeaud, (unknown), Ingrid Millet, F. Curros Doyon, (unknown), (unknown), J-L. Pujol	2
7	[Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management]. 2006 ·PubMed ·J-L. Pujol, Xavier Quantin, William Jacot, (unknown), (unknown)	1
8	CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients 2004 ·British Journal of Cancer ·J-L. Pujol, Olivier Molinier, W. Ébert, Daurès Jp, Fabrice Barlési, G Buccheri, M Paesmans, Élisabeth Quoix, Denis Moro‐Sibilot, M Szturmowicz, (unknown), T. Muley, Jean‐Christophe Grenier	164
9	Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer 2004 ·British Journal of Cancer ·William Jacot, J-L. Pujol, Jean‐Marie Boher, Pierre‐Jean Lamy	15
10	Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes 2004 ·Lung Cancer ·Thierry Le Chevalier, Giorgio V. Scagliotti, Ronald B. Natale, Sarah Danson, Rafael Rosell, Rolf A. Stahel, P. Thomas, R.M. Rudd, Johan Vansteenkiste, N. Thatcher, C. Manegold, J-L. Pujol, Nico van Zandwijk, Cesare Gridelli, Jan P. van Meerbeeck, Lucio Crinò, Alexander Brown, Patrick Fitzgerald, M Aristides, Joan H. Schiller	225
11	Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors 2001 ·British Journal of Cancer ·William Jacot, Xavier Quantin, Jean‐Marie Boher, Fabrice André, (unknown), (unknown), A Depierre, Élisabeth Quoix, T. Le Chevalier, J-L. Pujol	58
12	Concomitant brain radiotherapy and vinorelbine–ifosfamide–cisplatin chemotherapy in brain metastases of non-small cell lung cancer 1999 ·Lung Cancer ·Xavier Quantin, (unknown), M. Reme-Saumon, F B Michel, J-L. Pujol	28
13	Cost evaluation of breast cancer screening in France 1998 ·Academic Radiology ·(unknown), J-L. Pujol, (unknown), Julien Laurent, Patrice Taourel, (unknown), J.-P. Daurès, Fabienne Séguret, Anne‐Valérie Guizard, (unknown), (unknown)	1
14	Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer 1993 ·British Journal of Cancer ·J-L. Pujol, E H Cooper, M Lehmann, (unknown), (unknown), (unknown), Philippe Godard, F.B. Michel	9
15	Identification of an Alveolar Macrophage-derived Activity in Bronchial Asthma that Enhances Leukotriene C ₄ Generation by Human Eosinophils Stimulated by lonophore A23187 as a Granulocyte-macrophage Colony-stimulating Factor 1989 ·American Review of Respiratory Disease ·(unknown), J-L. Pujol, Attilio Crea, Robert G. Davidson, A. J. H. Gearing, (unknown), (unknown)	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact